|
1
|
Giesexs A and Westphal M: Glioma invasion
in the central nervous system. Neurosurgery. 39:235–250. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bush NA, Chang SM and Berger MS: Current
and future strategies for treatment of glioma. Neurosurg Rev.
40:1–14. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Omuro A and Deangelis LM: Glioblastoma and
other malignant gliomas: A clinical review. JAMA. 310:1842–1850.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hopkins K, Chandler C, Eatough J, Moss T
and Kemshead JT: Direct injection of 90Y MoAbs into glioma tumor
resection cavities 1eads to limited diffusion of the
radioimmunoconjugates into nomal brain parenchyma: A model to
estimate absorbed radiation dose. Int J Radiat Oncol Biol Phys.
40:835–844. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rudà R, Reifenberger G, Frappaz D, Pfister
SM, Laprie A, Santarius T, Roth P, Tonn JC, Soffietti R, Weller M
and Moyal EC: EANO guidelines for the diagnosis and treatment of
ependymal tumors. Neuro Oncol. 27:445–456. 2017.
|
|
6
|
Freije WA, Castro-Vargas FE, Fang Z,
Horvath S, Cloughesy T, Liau LM, Mischel PS and Nelson SF: Gene
expresion profiling of glioma strongly predicts survival. Cancer
Res. 64:6503–6510. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nicholson RI, Gee JM and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37 (Suppl 4):S9–S15. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Normanno N, De Luca A, Bianco C, Strizzi
L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F and
Salomon DS: Epidermal growth factor receptor (EGFR) signaling in
cancer. Gene. 366:2–16. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gadji M, Crous AM, Fortin D, Krcek J,
Torchia M, Mai S, Drouin R and Klonisch T: EGF receptor inhibitors
in the treatment of glioblastma multiform: Old clinicalallies and
newly emerging therapeutic concepts. EurJ Pharmacol. 25:23–30.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Muracciole X, Romain S, Dufour H, Palmari
J, Chinot O, Ouafik L, Grisoli F, Branger DF and Martin PM: PAI-1
and EGFR expression in adult glioma tumors: Toward a molecular
prognostic classification. Int J Radiat Oncol Biol Phys.
52:592–598. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun Y, Zhang W, Chen D, Lv Y, Zheng J,
Lilljebjörn H, Ran L, Bao Z, Soneson C, Sjögren HO, et al: A glioma
classification scheme based on coexpression modules of EGFR and
PDGFRA. Proc Natl Acad Sci USA. 111:3538–3543. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin T, Wang M, Liang HS and Liu EZ: The
expression of p53, mgmt and egfr in brain glioma and clinical
significance. J Biol Regul Homeost Agents. 29:143–149.
2015.PubMed/NCBI
|
|
13
|
Ladanyi M and Pao W: Lung adenocarcinoma:
Guiding EGFR-targeted therapy and beyond. Mod Pathol. 21 (Suppl
2):S16–S22. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lo HW: EGFR-Targeted therapy in malignant
glioma: Novel aspects and mechanisms of drug resistance. Curr Mol
Pharmacol. 3:37–52. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Giaccone G: The role of gefitinib in lung
cancer treatment. Clin Cancer Res. 10:4233s–4237s. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hotta K, Ueoka H, Kiura K, Tabata M, Ogino
A, Umemura S, Harita S, Gemba K, Yonei T, Bessho A, et al: Safety
and efficacy of gefitinib treatment in elderly patients with
non-small-cell lung cancer: Okayama lung cancer study group
experience. Acta Oncol. 44:717–722. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ostoros G, Harisi R, Kovacs G, Horti J,
Geczi L, Szondy K, Orosz M, Ferenczi E, Ruby E and Dome B:
Inhibition of EGFR tyrosine-kinase in NSCLC treatment: The
hungarian experience with gefitinib in the context of an expanded
access programme. Anticancer Res. 25:4759–4762. 2005.PubMed/NCBI
|
|
18
|
Antipenko L, Karpenko A, Kovalenko S,
Katsev A, Komarovska-Porokhnyavets E, Novikov V and Chekotilo A:
Synthesis of New 2-Thio-(1,2,4)triazolo(1, 5-c)quinazoline
derivatives and its antimicrobial activity. Chem Pharm Bull
(Tokyo). 57:580–585. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Latli B, Wood E and Casida EJ:
Insecticidal quinazoline derivatives with (trifluor-omethyl)
diazirinyl and azido substituents as NADH: Ubiquinone
oxidoreductase inhibitors and candidate photoaffinity probes. Chem
Res Toxicol. 9:445–450. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schleiss M, Eickhoff J, Auerochs S, Leis
M, Abele S, Rechter S, Choi Y, Anderson J, Scott G and Rawlinson W:
Protein kinase inhibitors of the quinazoline class exert
anti-cytomegaloviral activity in vitro and in vivo. Antiviral Res.
79:49–61. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Barker AJ: Quinazoline derivatives useful
for treatment of neoplastic disease. US Patent 5457105A. Filed
August 2, 1994; issued October 10, 1995.
|
|
22
|
Lokker NA, Sullivan CM, Hollenbach SJ,
Israel MA and Giese NA: Platelet-Derived growth factor (PDGF)
autocrine signaling regulates survival and mitogenic pathways in
glioblastoma cells: Evidence that the novel PDGF-C and PDGF-D
ligands may play a role in the development of brain tumors. Cancer
Res. 62:3729–3735. 2002.PubMed/NCBI
|
|
23
|
Cheng Y and Paz K: Tandutinib, an oral,
small-molecule inhibitor of FLT3 for the treatment of AML and other
cancer indications. IDrugs. 11:46–56. 2008.PubMed/NCBI
|
|
24
|
Fan TJ, Han LH, Cong RS and Liang J:
Caspase family proteases and apoptosis. Acta Biochim Biophys Sin
(Shanghai). 37:719–727. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li GH, Zhang H, Liu Y, Kong L, Guo Q and
Jin F: Effect of temozolomide on livin and caspase-3 in U251 glioma
stem cells. Exp Ther Med. 9:744–750. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang L, Hou L, Sun W, Yu Z, Wang J, Gao H
and Yang G: Synthesis of p-O-Alkyl salicylanilide derivatives as
novel EGFR inhibitors. Drug Dev Res. 77:37–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yin KH, Hsieh YH, Sulake RS, Wang SP, Chao
JI and Chen C: Optimization of gefitinib analogues with potent
anticancer activity. Bioorg Med Chem Lett. 24:5247–5250. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou J, Kwang KJ, Wu Z, Yang D, Li J,
Chang M, Song Y, Zeng H, Lee LJ, Hu J and Bai C: PLAUR confers
resistance to gefitinib through EGFR/P-AKT/Survivin signaling
pathway. Cell Physiol Biochem. 47:1909–1924. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Blazar IN: Differential effects of
epidermal growth factor receptor inhibitors on glioblastoma
multiforme (unpublished PhD thesis). Boston University Theses &
Dissertations. 2015.
|
|
30
|
Li Y, Raffo AT, Drew L, Mao Y, Tran A,
Petrylak DP and Fine RL: Fas-Mediated apoptosis is dependent on
wild-type p53 status in human cancer cells expressing a temperature
sensitive p53 mutant alanine-143. Cancer Res. 63:1527–1533.
2003.PubMed/NCBI
|
|
31
|
Chhanabhai M, Krajewski S, Krajewska M,
Wang HG, Reed JC and Gascoyne RD: Immunohistochemical analysis of
interleukin-1beta-convertin enzyme/Ced-3 family protease,
CPP32/Yama/Caspase-3, in Hodgkin's disease. Blood. 15:2451–2455.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Riedl SJ and Shi Y: Molecular mechanisms
of caspase regulation during apoptosis. Nat Rev Mol Cell.
5:897–907. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Creagh EM, Conroy H and Martin SJ:
Caspase-Activation pathways in apoptosis and immunity. Immunol Rev.
193:10–21. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Leung SY, Chan AS, Wong MP, Yuen ST,
Cheung N and Chung LP: Expression of vascular endothelial growth
factor and its receptors in pilocytic astrocytoma. Am J Surg
Pathol. 21:941–950. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lassoued W, Murphy D, Tsai J, Oueslati R,
Thurston G and Lee WM: Effect of VEGF and VEGF trap on vascular
endothelial cell signaling in tumor. Cancer Biol Ther.
10:1326–1333. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nesbit M: Abrogation of tumor vasculature
using gene therapy. Cancer Metastasis Rev. 19:45–49. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kil WJ, Tofilon PJ and Camphausen K:
Post-Radiation in crease in VEGF enhances glioma cell motility in
vitro. Radiat Oncol. 7:252012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Herbst RS and Shin DM: Monoclonal antibody
to target epidermal growth factor receptor positive tumors: A new
paradigm for cancer therapy. Cancer. 94:1593–1611. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pore N, Jiang Z, Gupta A, Cerniglia G, Kao
GD and Maity A: EGFR tyrosine kinase inhibitors decrease VGFR
expression by both hypoxia-inducible factor(HIF)-1-Dependent
mechanism. Cancer Res. 66:3197–3204. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bronte G, Terrasi M, Rizzo S, Sivestris N,
Ficorella C, Cajozzo M, Di Gaudio F, Gulotta G, Siragusa S, Gebbia
N and Russo A: EGFR genomic alterations in cancer: Prognostic and
predictive value. Front Biosci (Elite ED). 1:879–887.
2011.PubMed/NCBI
|
|
42
|
Tao JJ, Castel P, Radosevic-Robin N,
Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B,
Ellis H, et al: Antagonism of EGFR and HER3 enhances the response
to inhibitors of the PI3K-Akt pathway in triple-negative breast
cancer. Sci Signal. 7:ra29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lien EC, Dibble CC and Toker A: PI3K
signaling in cancer: Beyond AKT. Curr Opin Cell Biol. 45:62–71.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
McCubrey JA, Steelman LS, Abrams SL, Lee
JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA,
D'Assoro AB, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT
pathways in malignant transformation and drug resistance. Adv
Enzyme Regul. 46:249–279. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Freudlsperger C, Burnett JR, Friedman JA,
Kannabiran VR, Chen Z and Van Waes C: EGFR-PI3K-AKT-mTOR signaling
in head and neck squamous cell carcinomas-attractive targets for
molecular-oriented therapy. Expert Opin Ther Targets. 15:63–74.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Luwor RB, Taylor LE, Wang B and Zhu HJ:
Tumor-associated EGFR over-expression specifically activates Stat3
and Smad7 resulting in desensitization of TGF-β signaling. Nat
Prec. 2008. View Article : Google Scholar
|
|
47
|
Kim SH, Juhnn YS and Song YS: Akt
involvement in paclitaxel chemoresistance of human ovarian cancer
cells. Ann N Y Acad Sci. 10:82–89. 2007. View Article : Google Scholar
|
